Objective analysis INVION, page-2

Welcome to biotechs, where:

* companies will not have any revenue or hope for revenue for many years
* your hope is invested in intellectual property, and usually just a couple narrow pieces
* companies raise just enough money to not dilute the heck out of themselves, but probably need to raise more to dilute themselves
* the price is dependent on a few binary events

Not many of the current buyers bought for the science. The science has not changed nor been proven a failure in the past year. People bought for other reasons, such as according to analysts who decided it was a buy at 10 cents, and a sell at 2 cents a couple months later (huh?!?). Unfortunately it's all driven by market sentiment and my sentiment does not change according to stock price unless the executives are all dumping. So I still stick by what I said a few months ago. It is a great risk to take at the 2.5 cent issue.